Dianthus Therapeutics, Inc.
DNTH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001690585
In the last 90 days, Dianthus Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 269 institutions reported holding it in 13F filings for Q2 2026, worth $6.40B in total; no superinvestor holds it.
13F holders, Q3 2021
Institutional positions in Dianthus Therapeutics, Inc. as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 93
- −4 vs. Q2 2021
- Shares held
- 37.9M
- +444.6K (+1.2%) vs. Q2 2021
- Total value
- $276.0M
- −$90.4M (−24.7%) vs. Q2 2021
- New holders
- 15
- 31 more added
- Sold out
- 19
- 24 more reduced
Compare with Q2 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DNTH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 269 | $6.40B |
| Q1 2026 | 241 | $5.18B |
| Q4 2025 | 166 | $2.02B |
| Q3 2025 | 140 | $1.84B |
| Q2 2025 | 103 | $728.6M |
| Q1 2025 | 99 | $685.5M |
| Q4 2024 | 96 | $765.7M |
| Q3 2024 | 91 | $858.7M |
| Q2 2024 | 74 | $768.8M |
| Q1 2024 | 76 | $782.3M |
| Q4 2023 | 39 | $106.5M |
| Q3 2023 | 30 | $136.3M |
| Q2 2023 | 46 | $22.0M |
| Q1 2023 | 52 | $23.6M |
| Q4 2022 | 54 | $11.1M |
| Q3 2022 | 72 | $65.8M |
| Q2 2022 | 75 | $54.6M |
| Q1 2022 | 93 | $138.9M |
| Q4 2021 | 94 | $211.4M |
| Q3 2021 | 93 | $276.0M |
| Q2 2021 | 97 | $366.3M |
| Q1 2021 | 90 | $418.4M |
Institutions, Q3 2021
Shares, value and share of portfolio for each institution holding Dianthus Therapeutics, Inc.; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| PDT Partners, LLC | 0 | $0 | 0.00% | −25,200−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −23,500−100.0% | Sold out |
| Price T Rowe Associates Inc | 0 | $0 | 0.00% | −22,558−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −20,600−100.0% | Sold out |
| Manufacturers Life Insurance Company, The | 0 | $0 | 0.00% | −19,745−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −14,979−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −13,082−100.0% | Sold out |
| Raymond James & Associates | 0 | $0 | 0.00% | −11,200−100.0% | Sold out |
| Penn Mutual Asset Management, LLC | 0 | $0 | 0.00% | −9,144−100.0% | Sold out |
| Panagora Asset Management Inc | 0 | $0 | 0.00% | −565−100.0% | Sold out |
| AdvisorNet Financial, Inc | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| Ellevest, Inc. | 0 | $0 | 0.00% | −40−100.0% | Sold out |